What is HC Wainwright’s Forecast for HURA Q2 Earnings?

TuHURA Biosciences (NASDAQ:HURA) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for TuHURA Biosciences in a report released on Monday, March 3rd. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. HC Wainwright also issued estimates for TuHURA Biosciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.11) EPS, Q1 2026 earnings at ($0.10) EPS and Q2 2026 earnings at ($0.11) EPS.

HURA has been the topic of several other research reports. Rodman & Renshaw started coverage on TuHURA Biosciences in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective on the stock. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th.

TuHURA Biosciences Stock Performance

Shares of NASDAQ HURA opened at $2.09 on Thursday. The company’s 50 day moving average price is $4.03. TuHURA Biosciences has a 52-week low of $1.89 and a 52-week high of $14.60.

Institutional Trading of TuHURA Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new stake in shares of TuHURA Biosciences during the 4th quarter worth approximately $54,000. Squarepoint Ops LLC acquired a new stake in TuHURA Biosciences in the 4th quarter valued at approximately $223,000. OMERS ADMINISTRATION Corp acquired a new stake in TuHURA Biosciences in the 4th quarter valued at approximately $128,000. Millennium Management LLC acquired a new stake in TuHURA Biosciences in the 4th quarter valued at approximately $138,000. Finally, Bank of America Corp DE acquired a new stake in TuHURA Biosciences in the 4th quarter valued at approximately $59,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.